17 β -estradiol (E2) will be administered as a medicated feed and is only available to FDA approved facilities. The primary goal of studies conducted under INAD #12-671 is to generate data evaluating the efficacy of E2 administered in feed to larval brook and brown trout to produce feminized male fish that produce eggs. The treatment option that is allowed for brook trout is a dose of 20 mg active drug/kg feed at 4% body weight per day to fry for 60 days. The treatment option that is allowed for brown trout is a dose of 20 mg active drug/kg feed at 4% body weight per day to fry for 120 days. No retreatment will be allowed. No release of treated fish with E2 will be allowed. This INAD requires all participants to be approved by the FDA Environmental Team prior to participation – this review will take 100 days. To participate in the INAD Program for E2 visit the data collecting site.
Please read the Study Protocol prior to any treatments. It contains the protocol, SDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson .
Drug Source
Sigma-Aldrich, Inc
3306, 3300 S 2nd Street
St. Louis, MO 63118
United States
Brook and Brown Trout: 20 mg 17 β E2/kg feed at 4% body weight per day
- 60 consecutive days for Brook Trout
- 120 consecutive days for Brown Trout
No release of treated fish with E2
Investigator needs to report general fish behavior and any adverse effects relating to treatment.
- No re-treatment of fish is allowed.
- Investigator must follow all instructions in the Study Protocol for INAD 12-671 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements.
- Investigator must complete Facility Effluent Information Form for discharge of 17 β E2 before use under the INAD. Contact AADAP for more information.
- Any facility that wants to receive progeny from estradiol bloodstock must be approved by FDA. Contact AADAP for more information.
- Drug discharge must be in compliance with local NPDES permitting requirements.